Clinical Trial Update: A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain

View source ↗

Summary

The prolonged-release tapentadol hydrochloride trial in Filipino patients with moderate to severe chronic noncancer pain has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Noncancer Pain

Drugs mentioned

• Tapentadol hydrochloride prolonged-release (tapentadol)

Snippet

Sponsor: Janssen Pharmaceutica | Conditions: Moderate to Severe Chronic Non-cancer Pain | Status: WITHDRAWN